In the past week, CRMD stock has gone down by -6.44%, with a monthly gain of 43.79% and a quarterly surge of 67.61%. The volatility ratio for the week is 12.53%, and the volatility levels for the last 30 days are 7.78% for CorMedix Inc The simple moving average for the last 20 days is 15.48% for CRMD stock, with a simple moving average of 46.65% for the last 200 days.
Is It Worth Investing in CorMedix Inc (NASDAQ: CRMD) Right Now?
Moreover, the 36-month beta value for CRMD is 1.77. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRMD is 53.86M and currently, short sellers hold a 15.31% of that float. On April 19, 2024, CRMD’s average trading volume was 560.67K shares.
CRMD) stock’s latest price update
CorMedix Inc (NASDAQ: CRMD) has seen a rise in its stock price by 0.81 in relation to its previous close of 5.42. However, the company has experienced a -6.44% decline in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-15 that The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
Analysts’ Opinion of CRMD
Many brokerage firms have already submitted their reports for CRMD stocks, with RBC Capital Mkts repeating the rating for CRMD by listing it as a “Outperform.” The predicted price for CRMD in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on August 10, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see CRMD reach a price target of $31. The rating they have provided for CRMD stocks is “Buy” according to the report published on February 17th, 2021.
JMP Securities gave a rating of “Mkt Outperform” to CRMD, setting the target price at $22 in the report published on September 29th of the previous year.
CRMD Trading at 37.43% from the 50-Day Moving Average
After a stumble in the market that brought CRMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.94% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 12.53%, as shares surge +38.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +84.34% upper at present.
During the last 5 trading sessions, CRMD fell by -7.20%, which changed the moving average for the period of 200-days by +46.88% in comparison to the 20-day moving average, which settled at $4.81. In addition, CorMedix Inc saw 45.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRMD starting from Todisco Joseph, who purchase 13,561 shares at the price of $3.74 back on Mar 13 ’24. After this action, Todisco Joseph now owns 352,839 shares of CorMedix Inc, valued at $50,718 using the latest closing price.
DUNTON ALAN W, the Director of CorMedix Inc, purchase 3,000 shares at $3.30 during a trade that took place back on Dec 15 ’23, which means that DUNTON ALAN W is holding 15,250 shares at $9,900 based on the most recent closing price.
Stock Fundamentals for CRMD
Current profitability levels for the company are sitting at:
- -1403.21 for the present operating margin
- -4.13 for the gross margin
The net margin for CorMedix Inc stands at 13519.73. The total capital return value is set at -0.5. Equity return is now at value -74.02, with -64.32 for asset returns.
Based on CorMedix Inc (CRMD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -48.11. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1141.37.
Currently, EBITDA for the company is -30.3 million with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of 8097.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.97.
Conclusion
To wrap up, the performance of CorMedix Inc (CRMD) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
